Pelthos Therapeutics Inc. Reports Ownership Change

TL;DR

Insider ownership change at Pelthos Therapeutics Inc. - details pending.

AI Summary

On April 2, 2026, Peter Greenleaf, a reporting person associated with Pelthos Therapeutics Inc., reported a change in beneficial ownership of securities. The filing details transactions related to these securities, but specific details on the nature of the transaction, number of shares, or dollar amounts are not provided in this excerpt.

Why It Matters

This filing indicates a change in the beneficial ownership of securities by a key individual, which could signal shifts in insider confidence or strategic holdings within Pelthos Therapeutics Inc.

Risk Assessment

Risk Level: medium — Form 4 filings can indicate insider trading activity, which may carry inherent risks depending on the nature of the transaction.

Key Players & Entities

• Pelthos Therapeutics Inc. (company) — Issuer
• Peter Greenleaf (person) — Reporting Person
• 0001919246 (company) — Pelthos Therapeutics Inc. CIK
• 0001363683 (person) — Peter Greenleaf CIK

FAQ

Key Financial Figures

• $20.30 — multiple trades at prices ranging from $20.30 to $20.78. The price reported in column
• $20.78 — trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above r
• $21.31 — multiple trades at prices ranging from $21.31 to $22.03. The price reported in column
• $22.03 — trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above r

Filing Documents

• wk-form4_1775509257.html (4)
• wk-form4_1775509257.xml (4) — 6KB
• 0001919246-26-000052.txt ( ) — 8KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * Greenleaf Peter (Last) (First) (Middle) C/O PELTHOS THERAPEUTICS INC. 4020 STIRRUP CREEK DRIVE, SUITE 110 (Street) DURHAM NORTH CAROLINA 27703 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol Pelthos Therapeutics Inc. [ PTHS ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 04/02/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 04/02/2026 S (1) 420 D $ 20.5151 (2) 25,058 D Common Stock 04/02/2026 S (1) 377 D $ 21.3614 (3) 24,681 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Explanation of Responses: 1. This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. 2. This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. 3. This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Remarks: /s/ Francis Knuettel II, by power of attorney 04/06/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * F